UY27233A1 - Conjugados de pregabalina-lactosa - Google Patents

Conjugados de pregabalina-lactosa

Info

Publication number
UY27233A1
UY27233A1 UY27233A UY27233A UY27233A1 UY 27233 A1 UY27233 A1 UY 27233A1 UY 27233 A UY27233 A UY 27233A UY 27233 A UY27233 A UY 27233A UY 27233 A1 UY27233 A1 UY 27233A1
Authority
UY
Uruguay
Prior art keywords
disorders
lactose
pregabaline
pregabalin
diseases
Prior art date
Application number
UY27233A
Other languages
English (en)
Inventor
Timothy R Hurley
Michael J Lovdahl
Brian TOBIAS
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27233A1 publication Critical patent/UY27233A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con la presente invención, se proporcionan compuestos de pregabalina- lactosa. También se proporciona como parte de la presente invención un nuevo método para tratar en un sujeto trastornos o enfermedades del sistema nervioso central, que incluyen trastornos de crisis convulsivas, dolor, depresión, ansiedad, trastornos del sueno, trastornos consuntivos, psicosis, discinesia tardía, enfermedades de Huntington o Parkinson, administrando al sujeto una cantidad farmacéuticamente eficaz de un conjugado de pregabalina-lactosa
UY27233A 2001-03-30 2002-03-27 Conjugados de pregabalina-lactosa UY27233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
UY27233A1 true UY27233A1 (es) 2002-10-31

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27233A UY27233A1 (es) 2001-03-30 2002-03-27 Conjugados de pregabalina-lactosa

Country Status (32)

Country Link
US (1) US7022678B2 (es)
EP (1) EP1377318A2 (es)
JP (1) JP2004524357A (es)
KR (1) KR20040008146A (es)
CN (1) CN1511043A (es)
AP (1) AP2003002873A0 (es)
AR (1) AR033024A1 (es)
BG (1) BG108193A (es)
BR (1) BR0208439A (es)
CA (1) CA2440468C (es)
CZ (1) CZ20032547A3 (es)
DO (1) DOP2002000356A (es)
EA (1) EA200300954A1 (es)
EC (1) ECSP034740A (es)
EE (1) EE200300480A (es)
GT (1) GT200200051A (es)
HU (1) HUP0303956A2 (es)
IL (1) IL157879A0 (es)
IS (1) IS6912A (es)
MA (1) MA27004A1 (es)
MX (1) MXPA03007437A (es)
NO (1) NO20034348L (es)
OA (1) OA12456A (es)
PA (1) PA8542101A1 (es)
PE (1) PE20021016A1 (es)
PL (1) PL369179A1 (es)
SK (1) SK11832003A3 (es)
SV (1) SV2003000928A (es)
TN (1) TNSN02038A1 (es)
UY (1) UY27233A1 (es)
WO (1) WO2002078747A2 (es)
ZA (1) ZA200306608B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
WO2007035789A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2009158343A1 (en) * 2008-06-23 2009-12-30 Teva Pharmaceutical Industries, Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010115612A2 (en) 2009-04-10 2010-10-14 Synthon B.V. Pregabalin compositions
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
DK1121114T3 (da) * 1998-10-16 2007-04-10 Warner Lambert Co Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser
DE60106968T2 (de) * 2000-11-30 2005-11-03 Pfizer Products Inc., Groton Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren

Also Published As

Publication number Publication date
IS6912A (is) 2003-08-14
SK11832003A3 (sk) 2004-04-06
ECSP034740A (es) 2003-12-24
JP2004524357A (ja) 2004-08-12
EA200300954A1 (ru) 2004-02-26
ZA200306608B (en) 2004-11-25
GT200200051A (es) 2002-11-15
AR033024A1 (es) 2003-12-03
BG108193A (en) 2004-09-30
IL157879A0 (en) 2004-03-28
AP2003002873A0 (en) 2003-09-30
KR20040008146A (ko) 2004-01-28
US20020187941A1 (en) 2002-12-12
DOP2002000356A (es) 2002-12-15
EE200300480A (et) 2003-12-15
PE20021016A1 (es) 2002-11-14
NO20034348D0 (no) 2003-09-29
WO2002078747A8 (en) 2003-12-04
OA12456A (en) 2004-08-24
WO2002078747A2 (en) 2002-10-10
CZ20032547A3 (en) 2004-04-14
TNSN02038A1 (fr) 2005-12-23
PL369179A1 (en) 2005-04-18
CA2440468A1 (en) 2002-10-10
NO20034348L (no) 2003-09-29
PA8542101A1 (es) 2002-10-28
SV2003000928A (es) 2003-07-29
CA2440468C (en) 2008-09-02
US7022678B2 (en) 2006-04-04
CN1511043A (zh) 2004-07-07
HUP0303956A2 (hu) 2004-04-28
EP1377318A2 (en) 2004-01-07
WO2002078747A3 (en) 2003-10-09
MA27004A1 (fr) 2004-12-20
MXPA03007437A (es) 2003-11-18
WO2002078747A9 (en) 2003-12-31
BR0208439A (pt) 2004-03-23

Similar Documents

Publication Publication Date Title
UY27233A1 (es) Conjugados de pregabalina-lactosa
DK1259243T3 (da) Bupropion-metabolitter, fremgangsmåde til deres fremstilling samt anvendelse deraf
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
BR0213358A (pt) Uso de flibanserina
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
BE2012C040I2 (es)
ES2195943T3 (es) Compuestos heteroaromaticos biciclicos y triciclicos.
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
HK1102991A1 (en) Pharmaceutical formulation of decitabine
EA200300503A1 (ru) Новые лекарственные композиции на основе солей тиотропия и солей салметерола
EA200300854A1 (ru) Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств
SG157231A1 (en) Substituted p-diaminobenzene derivatives
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
BRPI0409380A (pt) composições farmacêuticas
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
CR7060A (es) Conjugados de pregabalina-lactosa
BR0009194A (pt) Composição do resorcinol
BRPI0513395A (pt) uso de um esteróide para aumentar a permeabilidade cutánea
BR0105781A (pt) Derivados de acilamino-ciclopropano
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
ECSP993101A (es) Metodo para el tratamiento de enfermedades neovasculares oculares

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141113